Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX plus cetuximab versus FOLFOX plus bevacizumab for conversion therapy in RAS/BRAF wild-type right-sided colon cancer with initially unresectable liver-only metastases
ChiCTR2000035989Phase 3Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Oct 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cetuximab, bevacizumab, folinic acid, fluorouracil and oxaliplatin in colon cancer and colorectal cancer (CRC) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: conversion-to-resection rate. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
cetuximabbevacizumabfolinic acidfluorouraciloxaliplatin
03
Conditions
colon cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2000035989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035989.